Lung and Pleural Cancers Research and Clinical Center, Eskişehir Osmangazi University Eskişehir, Turkey
Translational Medicine Research and Clinical Center, Eskişehir, Turkey
Balkan Med J. 2022 Jul 22;39(4):246-254. doi: 10.4274/balkanmedj.galenos.2022.2022-3-26. Epub 2022 Jun 13.
miRNAs are involved in tumor pathogenesis and can therefore be determined in the primary tumor, plasma and serum, and body fluids. As in various cancers, their role in the diagnosis, prognosis, and treatment of patients with malignant pleural mesothelioma (MPM) may be important.
To analyze the predictive value of miR-16-5p, miR-29c-3p, miR-31-5p, miR-125a-5p, miR-320a, miR-484 and miR-532-5p expressions for diagnosis, prognosis and response to treatment in patients with MPM.
Prospective case-control study.
In the first phase of the study, blood samples were collected from 101 MPM patients before chemotherapy and from 24 healthy donors (HDs). In the second phase, the blood samples were collected from 74 MPM patients who had received chemotherapy when the best overall response and disease recurrence were determined. A quantitative real-time polymerase chain reaction was undertaken to detect the miRNA expression levels. The miRNA expression profiles of MPM patients were compared with those of HDs. The associations between the expression levels of miRNAs and prognosis and response to treatment were then evaluated.
All miRNAs, except miR-31-5p, were expressed differently in MPM relative to that in HDs. The expression level of miR-16-5p decreased when compared with that of HDs, and the expression levels of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p increased when compared with that of HDs. The sensitivity and specificity values of miR-29c-3p, miR-125a-5p, miR-320a, miR-484, and miR-532-5p for discriminating MPM from HDs were 85.9% and 59.1%, 95.1% and 62.5%, 87.1% and 79.2%, 82.2% and 58.3%, and 69.3% and 82.6%, respectively. After adjusting for the histological subtype, stage, and treatment, the miR-29c-3p, miR-125a-5p, and miR-484 were associated with longer survival. The miRNA expression levels did not change longitudinally for the determination of chemotherapy response and recurrence.
miRNAs may be useful in diagnosing patients with MPM and provides helpful information in determining the prognosis of patients.
miRNAs 参与肿瘤的发病机制，因此可以在原发性肿瘤、血浆和血清以及体液中确定。在各种癌症中，miRNAs 在恶性胸膜间皮瘤（MPM）患者的诊断、预后和治疗中的作用可能很重要。
分析 miR-16-5p、miR-29c-3p、miR-31-5p、miR-125a-5p、miR-320a、miR-484 和 miR-532-5p 的表达对 MPM 患者诊断、预后和治疗反应的预测价值。
前瞻性病例对照研究。
在研究的第一阶段，从 101 名 MPM 患者在化疗前和 24 名健康供体（HDs）采集血液样本。在第二阶段，当确定最佳总体反应和疾病复发时，从 74 名接受化疗的 MPM 患者采集血液样本。采用实时定量聚合酶链反应检测 miRNA 表达水平。将 MPM 患者的 miRNA 表达谱与 HDs 的表达谱进行比较。然后评估 miRNA 表达水平与预后和治疗反应之间的关系。
除 miR-31-5p 外，所有 miRNA 在 MPM 中的表达均与 HDs 不同。与 HDs 相比，miR-16-5p 的表达水平降低，miR-29c-3p、miR-125a-5p、miR-320a、miR-484 和 miR-532-5p 的表达水平升高。miR-29c-3p、miR-125a-5p、miR-320a、miR-484 和 miR-532-5p 鉴别 MPM 与 HDs 的敏感性和特异性值分别为 85.9%和 59.1%、95.1%和 62.5%、87.1%和 79.2%、82.2%和 58.3%和 69.3%和 82.6%。在调整组织学亚型、分期和治疗后，miR-29c-3p、miR-125a-5p 和 miR-484 与更长的生存时间相关。miRNA 表达水平在确定化疗反应和复发时没有发生纵向变化。
miRNAs 可能有助于诊断 MPM 患者，并为确定患者的预后提供有帮助的信息。
